Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Divoux M, Plocque A, Sevin M, Voillat L, Feugier P, Guerci-Bresler A, Girodon F, Broseus J |
Journal | CLINICAL CASE REPORTS |
Volume | 8 |
Pagination | 1774-1780 |
Date Published | SEP |
Type of Article | Article |
ISSN | 2050-0904 |
Mots-clés | lenalidomide, Myelodysplastic Syndrome, myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis, myeloproliferative syndrome, thrombocytosis |
Résumé | Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN-RS-T in the context of major platelet counts. |
DOI | 10.1002/ccr3.3026 |